Performance of the COBAS AMPLICOR HCV MONITOR Test, Version 2.0, an Automated Reverse Transcription-PCR Quantitative System for Hepatitis C Virus Load Determination

Guido Gerken, Giuseppe Colucci(Roche (Switzerland)), Ann Butcher(Roche (Switzerland)), Stephen Soviero(Roche (Switzerland)), Martin Trippler(Johannes Gutenberg University Mainz), T. Rothaar(Johannes Gutenberg University Mainz), M. J. Blunk(Roche (Switzerland)), Maria Grazia Rumi(University of Milan), R. Soffredini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Journal of Clinical Microbiology
January 1, 2000
10.1128/.38.6.2210-2214.2000
Cited by 3

Related Papers

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis
|Gut|2009|406
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
|Hepatology|2012|405